Literature DB >> 23707266

TRPA1 insensitivity of human sural nerve axons after exposure to lidocaine.

Reginald J Docherty1, Lionel Ginsberg, Saqiba Jadoon, Richard W Orrell, Anupam Bhattacharjee.   

Abstract

TRPA1 is an ion channel of the TRP family that is expressed in some sensory neurons. TRPA1 activity provokes sensory symptoms of peripheral neuropathy, such as pain and paraesthesia. We have used a grease gap method to record axonal membrane potential and evoked compound action potentials (ECAPs) in vitro from human sural nerves and studied the effects of mustard oil (MO), a selective activator of TRPA1. Surprisingly, we failed to demonstrate any depolarizing response to MO (50, 250 μM) in any human sural nerves. There was no effect of MO on the A wave of the ECAP, but the C wave was reduced at 250 μM. In rat saphenous nerve fibres MO (50, 250 μM) depolarized axons and reduced the C wave of the ECAP but had no effect on the A wave. By contrast, both human and rat nerves were depolarized by capsaicin (0.5 to 5 μM) or nicotine (50 to 200 μM). Capsaicin caused a profound reduction in C fibre conduction in both species but had no effect on the amplitude of the A component. Lidocaine (30 mM) depolarized rat saphenous nerves acutely, and when rat nerves were pretreated with 30 mM lidocaine to mimic the exposure of human nerves to local anaesthetic during surgery, the effects of MO were abolished whilst the effects of capsaicin were unchanged. This study demonstrates that the local anaesthetic lidocaine desensitizes TRPA1 ion channels and indicates that it may have additional mechanisms for treating neuropathic pain that endure beyond simple sodium channel blockade.
Copyright © 2013 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Human; Lidocaine; Local anaesthetic; Neuropathic pain; Neuropathy; Peripheral nerve; Saphenous nerve; Sural nerve; TRPA1

Mesh:

Substances:

Year:  2013        PMID: 23707266     DOI: 10.1016/j.pain.2013.04.030

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  7 in total

Review 1.  Ion channels and osteoarthritic pain: potential for novel analgesics.

Authors:  C A Staunton; R Lewis; R Barrett-Jolley
Journal:  Curr Pain Headache Rep       Date:  2013-12

2.  Monocytes expressing CX3CR1 orchestrate the development of vincristine-induced pain.

Authors:  Elizabeth A Old; Suchita Nadkarni; John Grist; Clive Gentry; Stuart Bevan; Ki-Wook Kim; Adrian J Mogg; Mauro Perretti; Marzia Malcangio
Journal:  J Clin Invest       Date:  2014-04-17       Impact factor: 14.808

3.  TRPA1 and TRPV1 are required for lidocaine-evoked calcium influx and neuropeptide release but not cytotoxicity in mouse sensory neurons.

Authors:  Mirjam Eberhardt; Thomas Stueber; Jeanne de la Roche; Christine Herzog; Andreas Leffler; Peter W Reeh; Katrin Kistner
Journal:  PLoS One       Date:  2017-11-15       Impact factor: 3.240

4.  Treatment of peripheral pain with low-dose local anesthetics by epidermal, epithelial and periosteal application.

Authors:  Thomas Michels; Seifollah Ahmadi; Nicole Graf
Journal:  Local Reg Anesth       Date:  2018-12-11

Review 5.  Topical Treatments and Their Molecular/Cellular Mechanisms in Patients with Peripheral Neuropathic Pain-Narrative Review.

Authors:  Magdalena Kocot-Kępska; Renata Zajączkowska; Joanna Mika; David J Kopsky; Jerzy Wordliczek; Jan Dobrogowski; Anna Przeklasa-Muszyńska
Journal:  Pharmaceutics       Date:  2021-03-26       Impact factor: 6.321

6.  SuperPain--a resource on pain-relieving compounds targeting ion channels.

Authors:  Björn O Gohlke; Robert Preissner; Saskia Preissner
Journal:  Nucleic Acids Res       Date:  2013-11-22       Impact factor: 16.971

7.  Lidocaine as an element of multimodal analgesic therapy in major spine surgical procedures in children: a prospective, randomized, double-blind study.

Authors:  Ilona Batko; Barbara Kościelniak-Merak; Przemysław J Tomasik; Krzysztof Kobylarz; Jerzy Wordliczek
Journal:  Pharmacol Rep       Date:  2020-04-15       Impact factor: 3.024

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.